Industry

Prestige Biopharma and Intas Pharmaceuticals Announce Partnership to Commercialize Bevacizumab Biosimilar in the US, Europe, Canada, MENA, Brazil, Mexico, South Africa, CIS and the SEA countries

SINGAPORE–(BUSINESS WIRE)–#HD204—Prestige Biopharma Limited (KRX: 950210, hereafter referred to as “Prestige”) and Intas Pharmaceuticals Limited (hereafter referred to as “Intas”) today announced that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige Biopharma’s bevacizumab biosimilar, in the US, Europe, Canada, MENA, Brazil, Mexico, South … [Read more…]

Acquired von Willebrand Disease (AvWD) Treatment Market Research Report 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Acquired von Willebrand Disease (AvWD) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030” report has been added to ResearchAndMarkets.com’s offering. The acquired von willebrand disease treatment market is anticipated to grow, at a CAGR of 5.86% during the forecast period of … [Read more…]

Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer

– Companies plan to discuss results with regulatory authorities – BOTHELL, Wash. & TOKYO–(BUSINESS WIRE)–Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline results from the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869) Cohort K evaluating PADCEV® (enfortumab vedotin-ejfv) in combination with Merck’s … [Read more…]

ReCor Medical and Otsuka Medical Devices Announce Primary Endpoint Met in the RADIANCE II US Pivotal Trial of the Paradise™ System for the Treatment of Hypertension

PALO ALTO, Calif.–(BUSINESS WIRE)–ReCor Medical, Inc. (“ReCor”) and Otsuka Medical Devices Co., Ltd., a fully owned subsidiary of Otsuka Holdings Co., Ltd., today announced that the RADIANCE II US FDA IDE pivotal trial evaluating the Paradise™ Ultrasound Renal Denervation (uRDN) System as a treatment for hypertension met its primary efficacy endpoint, demonstrating a statistically significant … [Read more…]

SMOORE Opens First PMTA Testing Laboratory in China

SHENZHEN, China–(BUSINESS WIRE)–SMOORE, the world’s largest vape manufacturer, today announced that is has opened China’s first non-clinical full-scale testing laboratory for Premarket Tobacco Product Applications (PMTA). A PMTA is an application that must be reviewed and approved by the Food and Drug Administration (FDA) before a new nicotine product can be legally marketed in the … [Read more…]

Insempra Announces Strategic Investment in Solena Materials

Strategic investment to support the foundation of Solena Materials, a spin-out from Imperial College London, accelerating the development of synthetic fibers for high-performance, intrinsically sustainable clothing MUNICH–(BUSINESS WIRE)–Insempra, a biology-powered company enabling businesses to make superior products in partnership with nature, today announces a strategic investment in Solena Materials Ltd (‘Solena’), a synthetic biology company. … [Read more…]

Smiths Detection named as Official Security Equipment Provider – Birmingham 2022 Commonwealth Games

LONDON–(BUSINESS WIRE)–Smiths Detection, a global leader in threat detection and security screening technologies, has today been announced as a sponsor and supplier of X-ray screening and detection equipment for the Birmingham 2022 Commonwealth Games, helping to create a secure environment for all attendees. The Games will attract over one million visitors between 28 July and … [Read more…]

Genetika+ Wins Prestigious European Funding to Bring Depression Drug Matching Platform to Market

TEL AVIV, Israel–(BUSINESS WIRE)–Genetika+, a company developing personalized medicine solutions to optimize treatment for psychiatric and neurological diseases, announced today an award of up to €17.5 million of grant funding combined with equity investment to bring NeuroKaire to market. This represents the maximum possible grant from the European Commission and will be used for the … [Read more…]

First-of-Its-Kind Partnership Provides Free Access to Digital Mental Health Treatments for All Newly Diagnosed Cancer Patients in the United Kingdom

LONDON–(BUSINESS WIRE)–Newly diagnosed cancer patients across the United Kingdom (UK) are now able to easily access innovative and effective treatments to support their mental health thanks to a new partnership between Macmillan Cancer Support and digital therapeutics company Big Health, makers of Sleepio and Daylight[i]. The partnership delivers on a shared vision to address the … [Read more…]

Monkeypox Emergency Declaration a Step in Right Direction, says AHF

LOS ANGELES–(BUSINESS WIRE)–#COVID19–While long overdue, AIDS Healthcare Foundation acknowledged the World Health Organization’s decision yesterday to declare the global monkeypox outbreak a Public Health Emergency of International Concern. It is unclear why nine of the 15 International Health Regulations (2005) Emergency Committee members were not in favor of the PHEIC declaration when the virus has … [Read more…]